Cardiol Therapeutics Inc. Stock Price - CRTPF

Best deals to access real time data!
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Cardiol Therapeutics Inc. CRTPF OTCMarkets Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.148 7.78% 2.05 2.05 1.80 1.90 1.902 16:00:05
Bid Price Ask Price Spread Spread % News
1.21 2.33 1.12 48.07% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
34 25,156 $ 1.8442 $ 46,393 13,127 1.62 - 10.00
Last Trade Time Type Quantity Stock Price Currency
15:56:19 10 $ 2.05 USD

Cardiol Therapeutics Inc. Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 53.05M 25.88M - - 18.99M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
146.90k $ - 0.00% - -

more financials information »

Cardiol Therapeutics Inc. News

Loading Messages....

Latest CRTPF Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CRTPF Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.26692.321.631.9413,458-0.21689-9.57%
1 Month2.89363.301.632.3911,715-0.8436-29.15%
3 Months3.55143.6181.622.5412,521-1.50-42.28%
6 Months3.834.901.623.2317,251-1.78-46.48%
1 Year3.706110.001.623.8419,358-1.66-44.69%
3 Years3.706110.001.623.8419,358-1.66-44.69%
5 Years3.706110.001.623.8419,358-1.66-44.69%

Cardiol Therapeutics Inc. Description

Cardiol Therapeutics Inc. is focused on producing pharmaceutical CBD products and developing innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. The Company's lead product, CardiolRx, is designed to be the safest and most consistent CBD formulation on the market. CardiolRx is pharmaceutically-produced, cGMP certified, and does not contain any THC. The Company plans to commercialize CardiolRx during 2019 in the billion-dollar market for medicinal cannabinoids in Canada and is pursuing market introduction opportunities in Europe and Latin America. Cardiol is planning an international clinical study of CardiolRx in acute myocarditis, a condition caused by inflammation in heart tissue, which remains the most common cause of sudden cardiac death in people less than 35 years of age and is a common cause of acute heart failure. The Company is also developing proprietary nanotechnology to deliver pharmaceutical CBD and other anti-inflammatory drugs directly to sites of inflammation in the heart that are associated with the development and progression of heart failure. Heart failure is the leading cause of death and hospitalization in North America with associated healthcare costs in the U.S. alone exceeding $30 billion.

Your Recent History
Cardiol Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.